Tumor-associated antigen presented by major histocompatibility complex on dendritic cell

The term “Tumor-associated antigens presented by major histocompatibility complex on antigen-presenting dendritic cell surface” refers to complexes formed when dendritic cells (DCs), which are professional antigen-presenting cells, process tumor-derived antigens (TAA) and display peptide fragments bound to major histocompatibility complex (MHC) molecules on their surface. This presentation is fundamental for the immune system’s recognition of cancer, as it enables the activation of naïve CD8+ T cells (via MHC class I, leading to cytotoxic T cell priming) and CD4+ T cells (via MHC class II, leading to helper function and humoral immunity), thus promoting anti-tumor immunity[1][2][3][4]. DCs are the most potent activators because of their ability to process antigens and provide necessary co-stimulatory signals. However, in the tumor microenvironment, dendritic cell function can be subverted, leading to reduced effectiveness and immune tolerance[2][3]. Therapeutically, these complexes are targets for vaccine strategies—such as loading ex vivo–derived DCs with tumor antigens to immunize patients[1][4]. The clinical relevance is high in cancer immunotherapy, though manipulating these complexes in vivo remains challenging due to both safety and efficacy concerns. Caveats: - The phrase refers to a **complex and dynamic antigen-peptide/MHC presentation process** rather than a single canonical gene, protein, or druggable target in the classical sense. Therefore, the target as named lacks the specificity of most structured drug targets (e.g., “PD-1 receptor” or “HER2 receptor”) and covers multiple possible antigen-MHC combinations on dendritic cells depending on tumor context and patient[1][2][4]. - The nomenclature is **not standard for drug discovery databases**, so would be flagged as **is_incorrect: true** due to being too broad, covering many possible targets rather than a single molecular entity, and not matching a defined protein or receptor name.

Other names

Tumor antigen-MHC complex on dendritic cellTAA-MHC complex on dendritic cellpeptide-MHC complex (tumor antigen/dendritic cell)

Induction of tumor-specific cytotoxic T lymphocyte (CTL) responses by presenting tumor antigens to CD8+ and CD4+ T cells - Promotion of adaptive anti-tumor immunity by antigen cross-presentation